Alteogen received approval for first product, Tergase in Korea. It will be a safer alternative to existing animal-derived hyaluronidase products. Eylea biosimilar approval in Europe expected in 2025.
What is covered in the Full Insight:
Company Overview
Tergase Approval and Market Potential
ALT-L9 Biosimilar Development
Financial Performance
Stock Market Performance and Outlook
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.